Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.52 |
| ▸ | RAB9A | P51151 | 7/20 | 0.52 |
| ▸ | LMNA | P02545 | 6/20 | 0.52 |
| ▸ | MAPT | P10636 | 5/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.52 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.52 |
| ▸ | RELA | Q04206 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 6/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 6/20 | 0.44 |
| ▸ | KIF11 | P52732 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3545321 | 0.78 | HTR2C (0.43) | MAPTMEN1KMT2AGAAALOX15 | |
| SCHEMBL3551076 | 0.77 | CNR2 (0.41) | MAPTMEN1KMT2AGAAALOX15 | |
| SCHEMBL3546317 | 0.77 | HTR2C (0.40) | RAB9ALMNAMEN1KMT2AGAA | |
| SCHEMBL3546577 | 0.76 | LMNA (0.41) | NPC1RAB9ALMNAMEN1KMT2A | |
| SCHEMBL3547244 | 0.75 | MAPT (0.47) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL3545018 | 0.74 | KCNQ2 (0.40) | LMNAGAA | |
| SCHEMBL3546473 | 0.74 | RORC (0.41) | RAB9ALMNAMEN1KMT2AGAA | |
| SCHEMBL3540203 | 0.73 | BCHE (0.39) | NPC1RAB9ALMNAMAPTMEN1 | |
| SCHEMBL3538998 | 0.73 | RORC (0.41) | RAB9ALMNAMEN1KMT2AGAA | |
| SCHEMBL3546454 | 0.73 | KCNQ2 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7662831-B2 | Tetracyclic indoles as potassium channel modulators | WYETH LLC (US) | 2010-02-16 | — | — | US | claimed |
| US-20080027090-A1 | TETRACYCLIC INDOLES AS POTASSIUM CHANNEL MODULATORS | WYETH (US) | 2008-01-31 | — | — | US | claimed |
| US-7662831-B2 | Tetracyclic indoles as potassium channel modulators | WYETH LLC (US) | 2010-02-16 | — | — | US | disclosed |
| US-7662831-B2 | Tetracyclic indoles as potassium channel modulators | WYETH LLC (US) | 2010-02-16 | — | — | US | disclosed |
| US-7662831-B2 | Tetracyclic indoles as potassium channel modulators | WYETH LLC (US) | 2010-02-16 | — | — | US | disclosed |
| US-20080027090-A1 | TETRACYCLIC INDOLES AS POTASSIUM CHANNEL MODULATORS | WYETH (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080027090-A1 | TETRACYCLIC INDOLES AS POTASSIUM CHANNEL MODULATORS | WYETH (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080027090-A1 | TETRACYCLIC INDOLES AS POTASSIUM CHANNEL MODULATORS | WYETH (US) | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027090-A1 | TETRACYCLIC INDOLES AS POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNA5, KCNK5 | NPC1 873/4885RAB9A 3548/4885LMNA 3274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.